US EditionPublished • loading... • Updated
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
Phase II study shows Q-1802 plus XELOX achieves up to 81.8% objective response rate with manageable safety in advanced gastric and gastroesophageal junction cancer patients.
- On Jan. 28, 2026, QureBio Ltd. revealed Phase Ib/II Q-1802 data at ASCO 2026 via Abstract #537934, enrolling 62 eligible CLDN18.2-positive, HER2-negative, treatment-naive advanced GC/GEJ patients.
- Chinese CDE recently approved the phase III trial, and Dr. Gong et al. concluded Q-1802 plus XELOX showed manageable safety and recommended 10 mg/kg for phase III.
- In the 60 efficacy‑evaluable patients, ORR was 70.0%, DCR 98.3%, and mPFS 11.3 months, with ORR reaching 73.0% in the 10 mg/kg cohort.
- Safety data show permanent discontinuation 6.5% due to TEAEs, no treatment‑related death, with Grade 3 thrombocytopenia 8.1%, neutropenia 6.5%, and anemia/WBC decrease/hypokalemia 4.8% each.
- Q-1802's mechanism involves ADCC, ADCP and adaptive immunity via DC and T cells; QureBio Ltd. describes it as highly selective with a favorable safety profile and novel potential for Claudin18.2‑positive solid tumors.
Insights by Ground AI
23 Articles
23 Articles
Watauga Democrat+22 Reposted by 22 other sources
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission about…
·Calhoun, United States
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left6Leaning Right2Center9Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 35%
C 53%
12%
Factuality
To view factuality data please Upgrade to Premium
